HC Wainwright & Co. Reiterates Buy on Crinetics Pharmaceuticals, Maintains $60 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating on Crinetics Pharmaceuticals (NASDAQ:CRNX) and maintained a $60 price target.
June 28, 2024 | 10:48 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating on Crinetics Pharmaceuticals and maintained a $60 price target.
The reiteration of a Buy rating and the maintenance of a $60 price target by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100